Arctic Pharma AS

Arctic Pharma AS is committed to developing innovative treatment for glycolytic cancers

Excecutive Chairman of the Board

Eirik Næss-Ulseth, M.Sc

Eirik Næss Ulseth holds a Master of Science (M.Sc.) and a Master of Business Administration (MBA). In the last 20 years he been working on establishing and developing high technology companies within electronics, IT and biotechnology sectors.

Board member

Professor Anne-Lise Børresen-Dale M.D, Ph.D

Anne-Lise Børresen-Dale, professor Emerita at the University of Oslo, Oslo University Hospital and Radium hospital. Børresen-Dale is among the leading geneticists in research on molecular biology of breast cancer, and her group was among the pioneers in expression profiling of breast carcinomas in collaboration with groups at Stanford. Her achievements are seminal for understanding breast cancer evolution and have had an enormous impact on our view of the complexity of breast cancer. She has authored more than 500 published scientific papers, book chapters, and invited reviews.

Board member

Professor Bjørn Steen Skålhegg, Ph.D.

Bjørn Steen Skålhegg holds a Ph.D. in biochemistry from the Institute for Basic Medical Sciences at the University of Oslo. He did his postdoctoral fellowship at the University of Washington, Seattle, USA, and has been engaged in a full-time professorship at the University of Oslo Medical School since 2001.

Board member

Sigurd Ørstavik, M.D, Ph.D.

Sigurd Ørstavik holds a Ph.D. from the University of Oslo and has extensive experience from positions in both public and private health companies. Such positions include postdocs at the University of Oslo/Norwegian Cancer Society and Medical Advisor at Novartis AS, as well as attending physician at Oslo University Hospital, Department of Oncology. Ørstavik is an author of numerous publications and is currently the Head of Evidence Generation in the Nordics and Baltics at Takeda AS.

Board member

Ken Roger Rosendal, M. Sc.

Ken Rosendal holds a Master of Science (M.Sc) in biochemistry from the University of Bergen. Including a 4 year stay at the EMBL Heidelberg, he has broad experience in drug discovery, biochemistry, cell- and structural biology. He was the CEO of Spermatech AS until 2015, and he is a co-founder of Arctic Pharma AS. Ken is currently employed as a Business Development Specialist in Life Science at Inven2.

Board member

Gunnar Hvammen

Mr. Hvammen has a degree from the Norwegian Business School (BI). Mr. Hvammen has been an independent founder, investor, CEO and board member in numerous companies, including S.D. Standard Drilling Plc, Songa Offshore ASA and Spectrum ASA.